4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cloudbreak Pharma Inc. (2592) operates in the Biotechnology industry and is headquartered in Irvine, United States with about 61 employees. Its market capitalization is roughly HK$1 billion. In the fiscal year ended 2025-12-31, 2592 reported $0M in revenue and ($68M) in net income.
Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases.
Interactive charts & full statements → Open the 2592 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $10M | $0M | $0M |
| Operating Income (EBIT) | ($107M) | ($37M) | ($36M) | ($24M) |
| Net Income | ($68M) | ($99M) | ($129M) | ($67M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $67M | $40M | $65M | $82M |
| Total Liabilities | $6M | $392M | $328M | $227M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2592 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms